Fosun Pharmaceutical’s XS-03 Gets NMPA Green Light for CRC Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...
Fosun Pharmaceutical
Fosun Pharma’s Tenapanor Approved in China for CKD Dialysis Patients
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received...
Fosun’s Plan to Take Henlius Private Fails After Shareholder Vote
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its plan...
Fosun Pharma Initiates Phase II Study for Glomerular Disease Treatment
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...
Fosun Pharmaceutical’s FCN-437c Accepted for NMPA Review for Breast Cancer Treatment
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has announced that another market approval...
10th National VBP Round Results Announced: Contracts Worth Over RMB1.3 Billion
The national Volume-Based Procurement (VBP) authorities have released comprehensive details regarding the 10th VBP round,...
Zhongheng Group and Fosun Pharmaceutical Form JV to Boost Overseas Business
China-based Zhongheng Group (SHA: 600252) has announced plans to establish a joint venture (JV) with...
National VBP Program Round 10: 195 Manufacturers Secure Winning Bids for 62 Drugs
The preliminary outcomes of the 10th round of China’s national volume-based procurement (VBP) program were...
Shenyang Hongqi Pharma Secures NMPA Approval for Pretomanid in TB Treatment
The National Medical Products Administration (NMPA) of China has officially approved pretomanid, developed by Shenyang...
Sisram Medical’s Alma Harmony and Alma Hybrid Receive EU Medical Device Certification
Sisram Medical Ltd (HKG: 1696), an Israel-based company and part of the Fosun Pharmaceutical Group...
Fosun Pharmaceutical Reports Q3 2024 Revenue Growth and R&D Progress
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report...
Shanghai Fosun Pharmaceutical Gets NMPA Clinical Clearance for Lymphoma Drug XS-04
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent pharmaceutical company based...
Shanghai Fosun Pharmaceutical’s SBK010 Stroke Treatment Accepted for NMPA Review
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
Shanghai Fosun Pharmaceutical Partners with State-owned Firms to Boost ASEAN Drug Trade
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in...
Fosun Pharmaceutical’s PD-1 Inhibitor HanSiZhuang Recommended for Approval by EMA’s CHMP
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a leading pharmaceutical company in...
Fosun Pharma to Acquire Full Stake in Fosun Kite Biotechnology for USD 27 Million
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has disclosed plans to acquire...
Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Aesthetic Use in China
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
Shanghai Fosun Pharmaceutical Reports 5.31% YOY Revenue Growth and Strong R&D Investment in 2024H1 Report
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...
Fosun Pharma’s Privatization of Henlius Includes Cash and Share Offers, Aims for Full Equity Control
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...
Sisram Medical Reports 2024 Interim Revenues with Growth in Key Regions and New Product Launches
Sisram Medical Ltd (HKG: 1696), an Israel-based subsidiary of the Fosun Pharmaceutical Group, has released...